At the Cold Spring Harbor Laboratory Conference on Blood-Brain Barriers, Dr. Sylvaine Guerit (Head of Preclinical Research) will present a poster detailing in vitro and in vivo results supporting Neuvasq’s Wnt surrogate antibody program in vascular retinopathies.
In addition, Professor Benoit Vanhollebeke (Université Libre de Bruxelles), scientific founder of Neuvasq, will serve as a keynote speaker, presenting recent discoveries on the molecular regulation of CNS barriers and the therapeutic implications of Wnt pathway modulation.
This conference is intended to foster the cross-disciplinary exchange of ideas and expertise between developmental and evolutionary biologists, vascular and BBB physiologists, and disease-oriented industry scientists interested in modifying or circumventing specific pathways of neuroprotection.
Neuvasq’s lead program focuses on the development of engineered Wnt surrogate antibodies targeting Gpr124 and Reck, critical co-receptors in Wnt/β-catenin signaling.
Cookie policy